ET

Epics Therapeutics

BE0690.759.071

Gross margin
€ 4.23M ↑ 5% 2025 Total € 23.61M
Profit
€ -5.79M ↓ 20% 2025 Total € -33.32M
EBITDA
€ 926K ↑ 11% 2025 Total € 4.61M
EBIT
€ -5.49M ↓ 12% 2025 Total € -37.77M
Net profit
€ -5.79M ↓ 20% 2025 Total € -33.32M
Capex
€ 6.42M ↑ 17% 2025 Total € 42.88M
Assets
€ 14.71M ↑ 6% 2025
Equity
€ 9.11M ↑ 15% 2025
Debt
€ 5.59M ↓ 5% 2025
Cash
€ 10.20M ↑ 16% 2025
Cashflow
€ 618K ↓ 31% 2025 Total € 9.06M
Working capital
€ 9.87M ↑ 10% 2025
Current ratio
5.77 ↑ 13% 2025
Quick ratio
5.75 ↓ 32% 2025
Working capital ratio
6.28 ↓ 11% 2025
Debt
€ 5.59M ↓ 5% 2025
Short-term debt
€ 2.07M ↑ 19% 2025
Long-term debt
€ 3.52M ↓ 6% 2025
Debt / EBITDA
6.04 ↓ 15% 2025
Solvability
62.0% ↑ 4.8 pt 2025
Long term debt ratio
0.39 ↓ 17% 2025
Gross profitability
6.8% ↓ 4.5 pt 2025
Net profitability
-63.6% ↓ 2.4 pt 2025
Return On Assets (ROA)
-39.40 ↓ 13% 2025
Return On Equity (ROE)
-63.59 ↓ 4% 2025
Customer credit
98.98 2019
Days Sales Outstanding (DSO)
98.98 2019
Taxes
€ 34K ↑ 7% 2025 Total € 204K
Salaries and Social Security Contributions
€ 498K ↑ 10% 2025 Total € 3.49M
Employees
33.30 ↑ 5% 2025
Staff cost per employee
€ 15K ↑ 4% 2025